This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Namenda (oral solution)
Drug Names(s): memantine hydrochloride, Ebixa, Axura, SUN Y7017
Description: Memantine has been used in Germany for various forms of dementia for more than a decade. Memantine targets the NMDA glutamate receptor, whereas previously marketed anti-AD drugs target the enzyme acetylcholinesterase. Its mechanism of action is unclear, but persistent activation of central nervous system NMDA receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDAreceptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.
Namenda also showed antagonistic effects at the serotonin 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixthto one-tenth the potency.
The IR formulation is given twice daily and was approved in 2003. The ER formulation is once-daily.
BioMedTracker maintains separate profiles for the tablet and oral solution formulations of Namenda. Please also see Namenda (tablets).
Memantine was originally developed by the private Germany company, Merz. In Europe, it is marketed by Lundbeck. In the U.S., Forest is developing memantine with help from Neurobiological Technologies (NTI). Memantine is under development in Japan by Merz's partner Suntory.
Merz and Neurobiological Technologies
In April 1998, NTI announced a strategic research and marketing alliance with Merz and a new revenue sharing partnership with the Children's Medical Center Corporation (CMCC) of Boston, Massachusetts, to further the development and commercialization of Memantine.
Under this new collaboration, CMCC will terminate its existing license to NTI for AIDS-related dementia and neuropathic pain and grant exclusive rights to Merz. In exchange, NTI will...See full deal structure in Biomedtracker
Partners: Merz Pharmaceuticals GmbH Daiichi Sankyo Co., Ltd. H. Lundbeck A/S
Namenda (oral solution) News
Additional information available to subscribers only: